Sanofi Key Executives
This section highlights Sanofi's key executives, including their titles and compensation details.
Find Contacts at Sanofi
(Showing 0 of )
Sanofi Earnings
This section highlights Sanofi's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
April 24, 2025
Time:
Before Market
Est. EPS:
$1.67
Status:
Unconfirmed
Last Earnings Results
Date:
January 30, 2025
EPS:
$1.31
Est. EPS:
$1.65
Revenue:
$7.63B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-01-30 | $1.65 | $1.31 |
| Read Transcript | Q3 | 2024 | 2024-10-25 | $2.47 | $2.86 |
| Read Transcript | Q2 | 2024 | 2024-07-25 | $1.65 | $1.73 |
| Read Transcript | Q1 | 2024 | 2024-04-25 | $1.72 | $1.78 |
| Read Transcript | Q4 | 2023 | 2024-02-01 | $1.68 | $1.66 |
| Read Transcript | Q3 | 2023 | 2023-10-27 | $2.59 | $2.55 |
| Read Transcript | Q2 | 2023 | 2023-07-28 | $1.67 | $1.74 |
| Read Transcript | Q1 | 2023 | 2023-04-27 | $2.01 | $2.16 |
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Healthcare
Drug Manufacturers - General
$103.72
Stock Price
$126.96B
Market Cap
-
Employees
Paris, None
Location
Financial Statements
Access annual & quarterly financial statements for Sanofi, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $44.29B | $46.03B | $45.39B | $39.17B | $37.37B |
| Cost of Revenue | $13.21B | $14.24B | $13.69B | $12.26B | $12.16B |
| Gross Profit | $31.08B | $31.80B | $31.70B | $26.92B | $25.21B |
| Gross Profit Ratio | 70.18% | 69.10% | 69.83% | 68.70% | 67.47% |
| Research and Development Expenses | $7.39B | $6.73B | $6.71B | $5.69B | $5.53B |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $9.39B |
| Selling General and Administrative Expenses | $9.18B | $10.77B | $10.54B | $9.55B | $9.39B |
| Other Expenses | $7.25B | $6.45B | $2.57B | $2.53B | $2.40B |
| Operating Expenses | $23.83B | $23.94B | $19.81B | $17.77B | $17.32B |
| Cost and Expenses | $37.03B | $38.16B | $-7.29B | $30.03B | $29.48B |
| Interest Income | $413.00M | $546.00M | $206.00M | $40.00M | $53.00M |
| Interest Expense | $749.00M | $1.09B | $461.00M | $368.00M | $390.00M |
| Depreciation and Amortization | $3.59B | $3.78B | $3.70B | $3.13B | $3.27B |
| EBITDA | $11.03B | $12.00B | $14.06B | $11.29B | $17.51B |
| EBITDA Ratio | 24.91% | 26.06% | 30.98% | 27.47% | 26.13% |
| Operating Income | $7.25B | $7.88B | $16.79B | $8.13B | $8.08B |
| Operating Income Ratio | 16.38% | 17.11% | 37.00% | 20.74% | 21.63% |
| Total Other Income Expenses Net | $-554.00M | $-722.00M | $-166.00M | $-328.00M | $24.00M |
| Income Before Tax | $6.70B | $7.15B | $10.49B | $7.80B | $13.80B |
| Income Before Tax Ratio | 15.12% | 15.54% | 23.11% | 19.91% | 36.94% |
| Income Tax Expense | $1.20B | $1.60B | $2.01B | $1.56B | $1.81B |
| Net Income | $5.56B | $5.40B | $8.37B | $6.22B | $12.29B |
| Net Income Ratio | 12.55% | 11.73% | 18.44% | 15.89% | 32.90% |
| EPS | $4.44 | $4.31 | $6.69 | $4.97 | $9.81 |
| EPS Diluted | $4.44 | $4.30 | $6.66 | $4.95 | $9.76 |
| Weighted Average Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B |
| Weighted Average Shares Outstanding Diluted | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.63B | $14.16B | $11.38B | $11.12B | $22.88B | $12.70B | $10.68B | $10.86B | $11.46B | $13.14B | $10.74B | $10.05B | $10.41B | $10.83B | $9.04B | $8.89B | $9.74B | $9.88B | $8.44B | $9.32B |
| Cost of Revenue | $2.27B | $4.08B | $3.39B | $3.44B | $8.20B | $3.84B | $3.27B | $3.08B | $3.73B | $3.83B | $3.25B | $2.88B | $3.47B | $3.24B | $2.86B | $2.68B | $3.39B | $3.18B | $2.64B | $2.87B |
| Gross Profit | $5.36B | $10.07B | $7.99B | $7.68B | $14.68B | $8.86B | $7.41B | $7.78B | $7.72B | $9.31B | $7.49B | $7.17B | $6.94B | $7.59B | $6.19B | $6.20B | $6.35B | $6.70B | $5.80B | $6.45B |
| Gross Profit Ratio | 70.24% | 71.10% | 70.20% | 69.10% | 64.20% | 69.80% | 69.40% | 71.70% | 67.40% | 70.80% | 69.70% | 71.40% | 66.70% | 70.10% | 68.40% | 69.80% | 65.21% | 67.85% | 68.69% | 69.25% |
| Research and Development Expenses | $2.12B | $1.85B | $1.72B | $1.72B | $3.54B | $1.66B | $1.63B | $1.56B | $1.82B | $1.74B | $1.72B | $1.49B | $1.59B | $1.44B | $1.40B | $1.27B | $1.52B | $1.32B | $1.35B | $1.34B |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $58.00M | $- | $32.00M | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.60B | $- | $2.27B | $2.34B |
| Selling General and Administrative Expenses | $1.24B | $2.68B | $2.69B | $2.60B | $5.51B | $2.58B | $2.58B | $2.61B | $2.94B | $2.64B | $2.60B | $2.38B | $2.80B | $2.27B | $2.36B | $2.19B | $2.66B | $2.18B | $2.30B | $2.34B |
| Other Expenses | $1.43B | $1.90B | $1.98B | $- | $- | $- | $- | $793.00M | $590.00M | $280.00M | $892.00M | $714.00M | $731.00M | $674.00M | $562.00M | $490.00M | $460.00M | $- | $559.00M | $704.00M |
| Operating Expenses | $4.79B | $6.44B | $6.63B | $6.27B | $9.04B | $5.40B | $5.25B | $4.96B | $5.36B | $4.66B | $5.22B | $4.58B | $5.12B | $4.38B | $4.32B | $3.95B | $4.64B | $4.18B | $4.21B | $4.39B |
| Cost and Expenses | $7.06B | $10.52B | $10.02B | $9.71B | $17.25B | $9.24B | $8.52B | $-2.23B | $99.00M | $-2.75B | $-2.78B | $-1.87B | $-1.95B | $-1.32B | $-1.75B | $-1.45B | $-1.39B | $7.35B | $5.15B | $-1.38B |
| Interest Income | $- | $133.00M | $56.00M | $102.00M | $330.00M | $143.00M | $125.00M | $161.00M | $120.00M | $52.00M | $24.00M | $10.00M | $10.00M | $2.00M | $16.00M | $14.00M | $- | $76.00M | $8.00M | $23.00M |
| Interest Expense | $- | $265.00M | $135.00M | $253.00M | $1.08B | $318.00M | $202.00M | $168.00M | $180.00M | $103.00M | $101.00M | $88.00M | $127.00M | $87.00M | $112.00M | $99.00M | $- | $- | $100.00M | $98.00M |
| Depreciation and Amortization | $209.00M | $479.00M | $882.00M | $829.50M | $2.99B | $562.00M | $1.86B | $489.00M | $1.61B | $460.00M | $1.83B | $449.00M | $1.63B | $385.00M | $1.73B | $389.00M | $1.68B | $827.75M | $2.02B | $457.00M |
| EBITDA | $563.00M | $4.25B | $2.51B | $2.86B | $1.64B | $3.92B | $6.33B | $3.58B | $2.42B | $5.32B | $5.68B | $3.24B | $1.91B | $3.92B | $2.46B | $2.97B | $2.08B | $3.44B | $2.25B | $2.89B |
| EBITDA Ratio | 7.38% | 30.00% | 22.06% | 25.74% | 26.00% | 32.76% | 26.52% | 32.93% | 21.10% | 40.52% | 26.28% | 32.27% | 18.35% | 36.24% | 27.19% | 33.47% | 21.33% | 34.84% | 26.71% | 31.05% |
| Operating Income | $573.00M | $3.63B | $1.63B | $2.03B | $5.64B | $3.21B | $1.86B | $4.14B | $3.47B | $5.84B | $3.48B | $3.70B | $2.92B | $4.31B | $3.05B | $3.38B | $2.78B | $2.61B | $2.71B | $3.49B |
| Operating Income Ratio | 7.51% | 25.68% | 14.31% | 18.28% | 24.63% | 25.29% | 17.40% | 38.10% | 30.26% | 44.42% | 32.40% | 36.84% | 28.05% | 39.82% | 33.76% | 38.00% | 28.60% | 26.46% | 32.13% | 37.49% |
| Total Other Income Expenses Net | $-117.00M | $-132.00M | $-179.00M | $-139.00M | $-463.00M | $-175.00M | $-141.00M | $5.00M | $611.00M | $-44.00M | $-49.00M | $-48.00M | $-64.00M | $-85.00M | $-75.00M | $-76.00M | $-88.00M | $-75.00M | $5.46B | $83.00M |
| Income Before Tax | $456.00M | $3.50B | $1.42B | $1.31B | $2.92B | $3.04B | $1.78B | $2.47B | $4.08B | $2.68B | $1.38B | $2.35B | $1.41B | $2.95B | $1.48B | $1.98B | $1.39B | $2.45B | $8.17B | $2.13B |
| Income Before Tax Ratio | 5.98% | 24.74% | 12.44% | 11.78% | 12.74% | 23.91% | 16.68% | 22.72% | 35.60% | 20.40% | 12.87% | 23.37% | 13.51% | 27.26% | 16.36% | 22.30% | 14.31% | 24.79% | 96.78% | 22.85% |
| Income Tax Expense | $4.00M | $737.00M | $299.00M | $164.00M | $872.00M | $563.00M | $271.00M | $459.00M | $910.00M | $601.00M | $163.00M | $332.00M | $267.00M | $609.00M | $274.00M | $404.00M | $323.00M | $490.00M | $560.00M | $434.00M |
| Net Income | $499.00M | $2.81B | $1.11B | $1.13B | $-555.00M | $2.52B | $1.44B | $2.00B | $3.11B | $2.08B | $1.18B | $2.01B | $1.13B | $2.32B | $1.21B | $1.57B | $1.08B | $1.95B | $7.60B | $1.68B |
| Net Income Ratio | 6.54% | 19.88% | 9.78% | 10.19% | -2.43% | 19.89% | 13.43% | 18.37% | 27.16% | 15.80% | 10.94% | 19.98% | 10.86% | 21.40% | 13.38% | 17.62% | 11.10% | 19.76% | 90.05% | 18.07% |
| EPS | $0.40 | $2.25 | $0.89 | $0.91 | $-0.44 | $2.01 | $1.15 | $1.60 | $4.14 | $1.66 | $0.94 | $1.61 | $0.91 | $1.85 | $0.96 | $1.25 | $0.85 | $1.55 | $6.07 | $1.35 |
| EPS Diluted | $0.40 | $2.25 | $0.88 | $0.91 | $-0.44 | $2.01 | $1.15 | $1.60 | $4.12 | $1.66 | $0.94 | $1.61 | $0.91 | $1.85 | $0.95 | $1.25 | $0.85 | $1.55 | $6.01 | $1.35 |
| Weighted Average Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.25B |
| Weighted Average Shares Outstanding Diluted | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.26B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.26B | 1.25B | 1.26B | 1.26B | 1.27B | 1.25B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.44B | $8.71B | $12.74B | $10.10B | $13.91B |
| Short Term Investments | $486.00M | $- | $- | $- | $- |
| Cash and Short Term Investments | $7.93B | $8.71B | $12.74B | $10.10B | $13.91B |
| Net Receivables | $10.63B | $11.04B | $10.75B | $9.79B | $9.95B |
| Inventory | $9.43B | $9.67B | $8.96B | $8.71B | $8.35B |
| Other Current Assets | $14.60B | $1.24B | $1.58B | $1.96B | $1.48B |
| Total Current Assets | $42.59B | $30.66B | $34.03B | $30.56B | $33.70B |
| Property Plant Equipment Net | $11.60B | $11.81B | $11.68B | $11.98B | $10.56B |
| Goodwill | $43.38B | $49.40B | $49.89B | $48.06B | $44.36B |
| Intangible Assets | $22.63B | $24.32B | $21.64B | $21.41B | $18.34B |
| Goodwill and Intangible Assets | $66.01B | $73.72B | $71.53B | $69.46B | $62.70B |
| Long Term Investments | $3.26B | $3.26B | $3.22B | $2.91B | $2.67B |
| Tax Assets | $7.97B | $6.43B | $5.38B | $4.60B | $4.18B |
| Other Non-Current Assets | $1.37B | $588.00M | $882.00M | $731.00M | $600.00M |
| Total Non-Current Assets | $90.21B | $95.81B | $92.70B | $89.68B | $80.71B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $132.80B | $126.46B | $126.72B | $120.24B | $114.41B |
| Account Payables | $7.55B | $7.33B | $6.81B | $6.18B | $5.29B |
| Short Term Debt | $4.47B | $2.32B | $4.45B | $3.45B | $3.00B |
| Tax Payables | $1.13B | $597.00M | $574.00M | $309.00M | $604.00M |
| Deferred Revenue | $- | $- | $264.00M | $319.00M | $252.00M |
| Other Current Liabilities | $16.01B | $13.95B | $11.86B | $11.04B | $10.10B |
| Total Current Liabilities | $29.16B | $24.19B | $23.96B | $21.30B | $19.25B |
| Long Term Debt | $13.44B | $16.10B | $16.76B | $18.96B | $20.68B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $2.17B | $1.86B | $1.84B | $1.62B | $1.77B |
| Other Non-Current Liabilities | $10.18B | $9.96B | $9.00B | $9.34B | $9.47B |
| Total Non-Current Liabilities | $25.78B | $27.92B | $27.61B | $29.92B | $31.91B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $54.94B | $52.11B | $51.57B | $51.21B | $51.16B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.53B | $2.53B | $2.52B | $2.53B | $2.52B |
| Retained Earnings | $- | $67.50B | $66.73B | $63.01B | $60.15B |
| Accumulated Other Comprehensive Income Loss | $70.56B | $4.88B | $6.11B | $3.55B | $782.00M |
| Other Total Stockholders Equity | $4.42B | $-871.00M | $-581.00M | $-407.00M | $-343.00M |
| Total Stockholders Equity | $77.51B | $74.04B | $74.78B | $68.68B | $63.11B |
| Total Equity | $77.86B | $74.35B | $75.15B | $69.03B | $63.25B |
| Total Liabilities and Stockholders Equity | $132.80B | $126.46B | $126.72B | $120.24B | $114.41B |
| Minority Interest | $350.00M | $313.00M | $368.00M | $350.00M | $146.00M |
| Total Liabilities and Total Equity | $132.80B | $126.46B | $126.72B | $120.24B | $114.41B |
| Total Investments | $3.75B | $3.26B | $3.22B | $2.91B | $2.67B |
| Total Debt | $17.91B | $18.42B | $21.21B | $22.41B | $23.68B |
| Net Debt | $10.46B | $9.71B | $8.48B | $12.32B | $9.76B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.44B | $6.79B | $-8.71B | $8.71B | $-7.99B | $7.99B | $-12.74B | $12.74B | $-6.90B | $6.90B | $-10.11B | $10.10B | $-9.72B | $9.72B | $-13.91B | $13.91B | $-15.97B | $15.97B | $-9.43B | $9.74B |
| Short Term Investments | $486.00M | $- | $17.42B | $- | $15.99B | $- | $25.47B | $- | $13.80B | $- | $20.22B | $- | $19.44B | $- | $27.83B | $- | $31.94B | $- | $18.86B | $- |
| Cash and Short Term Investments | $7.93B | $6.79B | $8.71B | $8.71B | $7.99B | $7.99B | $12.74B | $12.74B | $6.90B | $6.90B | $10.11B | $10.10B | $9.72B | $9.72B | $13.91B | $13.91B | $15.97B | $15.97B | $9.43B | $9.74B |
| Net Receivables | $10.63B | $8.80B | $- | $11.04B | $- | $8.64B | $- | $10.75B | $- | $8.41B | $- | $9.79B | $- | $7.42B | $- | $9.95B | $- | $7.20B | $- | $10.08B |
| Inventory | $9.43B | $10.61B | $- | $9.67B | $- | $9.97B | $- | $8.96B | $- | $9.37B | $- | $8.71B | $- | $9.26B | $- | $8.35B | $- | $8.89B | $- | $7.99B |
| Other Current Assets | $14.60B | $3.87B | $- | $1.24B | $- | $3.37B | $- | $1.58B | $- | $3.69B | $- | $1.96B | $- | $3.09B | $- | $1.48B | $- | $2.73B | $- | $792.00M |
| Total Current Assets | $42.59B | $30.08B | $8.71B | $30.66B | $7.99B | $29.98B | $12.74B | $34.03B | $6.90B | $28.36B | $10.11B | $30.56B | $9.72B | $29.50B | $13.91B | $33.70B | $15.97B | $34.79B | $9.43B | $28.61B |
| Property Plant Equipment Net | $11.60B | $11.88B | $- | $11.81B | $- | $11.53B | $- | $11.68B | $- | $11.64B | $- | $11.98B | $- | $10.98B | $- | $10.56B | $- | $10.60B | $- | $11.02B |
| Goodwill | $43.38B | $50.08B | $- | $49.40B | $- | $49.24B | $- | $49.89B | $- | $50.55B | $- | $48.06B | $- | $44.98B | $- | $44.36B | $- | $45.25B | $- | $44.52B |
| Intangible Assets | $22.63B | $26.65B | $- | $24.32B | $- | $24.59B | $- | $21.64B | $- | $21.98B | $- | $21.41B | $- | $19.47B | $- | $18.42B | $- | $17.02B | $- | $16.57B |
| Goodwill and Intangible Assets | $66.01B | $76.73B | $- | $73.72B | $- | $73.83B | $- | $71.53B | $- | $72.53B | $- | $69.46B | $- | $64.44B | $- | $62.78B | $- | $62.27B | $- | $61.09B |
| Long Term Investments | $3.26B | $3.23B | $- | $3.26B | $- | $3.00B | $- | $3.22B | $- | $3.29B | $- | $2.91B | $- | $2.66B | $- | $2.67B | $- | $2.97B | $- | $5.99B |
| Tax Assets | $7.97B | $7.28B | $- | $6.43B | $- | $5.98B | $- | $5.38B | $- | $4.80B | $- | $4.60B | $- | $4.24B | $- | $4.21B | $- | $4.83B | $- | $5.43B |
| Other Non-Current Assets | $1.37B | $551.00M | $-8.71B | $588.00M | $-7.99B | $1.04B | $-12.74B | $882.00M | $-6.90B | $1.20B | $-10.11B | $731.00M | $-9.72B | $501.00M | $-13.91B | $600.00M | $-15.97B | $348.00M | $-9.43B | $595.00M |
| Total Non-Current Assets | $90.21B | $99.68B | $-8.71B | $95.81B | $-7.99B | $95.38B | $-12.74B | $92.70B | $-6.90B | $93.47B | $-10.11B | $89.68B | $-9.72B | $82.82B | $-13.91B | $80.83B | $-15.97B | $81.03B | $-9.43B | $84.12B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $132.80B | $129.75B | $- | $126.46B | $- | $125.35B | $- | $126.72B | $- | $121.83B | $- | $120.24B | $- | $112.32B | $- | $114.53B | $- | $115.82B | $- | $112.74B |
| Account Payables | $7.55B | $7.43B | $- | $7.33B | $- | $7.37B | $- | $6.81B | $- | $6.56B | $- | $6.18B | $- | $5.37B | $- | $5.29B | $- | $4.92B | $- | $5.31B |
| Short Term Debt | $4.47B | $9.52B | $- | $2.32B | $- | $4.95B | $- | $4.45B | $- | $3.29B | $- | $3.45B | $- | $2.47B | $- | $3.00B | $- | $3.58B | $- | $4.82B |
| Tax Payables | $1.13B | $132.00M | $- | $597.00M | $- | $377.00M | $- | $574.00M | $- | $443.00M | $- | $309.00M | $- | $588.00M | $- | $604.00M | $- | $- | $- | $613.00M |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $264.00M | $- | $- | $- | $319.00M | $- | $- | $- | $252.00M | $- | $- | $- | $- |
| Other Current Liabilities | $16.01B | $12.95B | $- | $13.95B | $- | $12.07B | $- | $11.86B | $- | $11.77B | $- | $11.04B | $- | $10.69B | $- | $10.10B | $- | $10.30B | $- | $9.64B |
| Total Current Liabilities | $29.16B | $30.03B | $- | $24.19B | $- | $24.76B | $- | $23.96B | $- | $22.06B | $- | $21.30B | $- | $19.13B | $- | $19.25B | $- | $18.80B | $- | $20.38B |
| Long Term Debt | $13.44B | $14.24B | $- | $16.10B | $- | $16.08B | $- | $16.76B | $- | $17.94B | $- | $18.96B | $- | $19.18B | $- | $20.68B | $- | $21.35B | $- | $21.12B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $2.17B | $1.80B | $- | $1.86B | $- | $1.95B | $- | $1.84B | $- | $1.55B | $- | $1.62B | $- | $1.67B | $- | $1.77B | $- | $1.98B | $- | $2.29B |
| Other Non-Current Liabilities | $10.18B | $10.70B | $- | $9.96B | $- | $9.62B | $- | $9.00B | $- | $8.97B | $- | $9.34B | $- | $8.98B | $- | $9.69B | $- | $10.21B | $- | $9.84B |
| Total Non-Current Liabilities | $25.78B | $26.73B | $- | $27.92B | $- | $27.65B | $- | $27.61B | $- | $28.46B | $- | $29.92B | $- | $29.83B | $- | $32.13B | $- | $33.53B | $- | $33.25B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $54.94B | $56.76B | $- | $52.11B | $- | $52.41B | $- | $51.57B | $- | $50.52B | $- | $51.21B | $- | $48.96B | $- | $51.38B | $- | $52.33B | $- | $53.63B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.53B | $2.53B | $- | $2.53B | $- | $2.52B | $- | $2.52B | $- | $2.53B | $- | $2.53B | $- | $2.52B | $- | $2.52B | $- | $2.51B | $- | $2.51B |
| Retained Earnings | $- | $65.09B | $- | $67.50B | $- | $65.69B | $- | $66.73B | $- | $61.88B | $- | $63.01B | $- | $59.05B | $- | $60.05B | $- | $57.06B | $- | $51.78B |
| Accumulated Other Comprehensive Income Loss | $70.56B | $6.12B | $74.04B | $4.88B | $72.63B | $5.23B | $74.78B | $6.11B | $70.95B | $7.15B | $68.68B | $3.55B | $63.24B | $2.00B | $63.00B | $780.00M | $63.30B | $3.79B | $58.93B | $4.51B |
| Other Total Stockholders Equity | $4.42B | $-1.05B | $313.00M | $-871.00M | $318.00M | $-817.00M | $368.00M | $-581.00M | $353.00M | $-614.00M | $350.00M | $-407.00M | $127.00M | $-335.00M | $146.00M | $-343.00M | $182.00M | $-63.00M | $174.00M | $138.00M |
| Total Stockholders Equity | $77.51B | $72.69B | $74.35B | $74.04B | $72.95B | $72.63B | $75.15B | $74.78B | $71.30B | $70.95B | $69.03B | $68.68B | $63.36B | $63.24B | $63.15B | $63.00B | $63.49B | $63.30B | $59.11B | $58.93B |
| Total Equity | $77.86B | $73.00B | $74.35B | $74.35B | $72.95B | $72.95B | $75.15B | $75.15B | $71.30B | $71.30B | $69.03B | $69.03B | $63.36B | $63.36B | $63.15B | $63.15B | $63.49B | $63.49B | $59.11B | $59.11B |
| Total Liabilities and Stockholders Equity | $132.80B | $129.75B | $74.35B | $126.46B | $72.95B | $125.35B | $75.15B | $126.72B | $71.30B | $121.83B | $69.03B | $120.24B | $63.36B | $112.32B | $63.15B | $114.53B | $63.49B | $115.82B | $59.11B | $112.74B |
| Minority Interest | $350.00M | $307.00M | $- | $313.00M | $- | $318.00M | $- | $368.00M | $- | $353.00M | $- | $350.00M | $- | $127.00M | $- | $146.00M | $- | $182.00M | $- | $174.00M |
| Total Liabilities and Total Equity | $132.80B | $129.75B | $74.35B | $126.46B | $72.95B | $125.35B | $75.15B | $126.72B | $71.30B | $121.83B | $69.03B | $120.24B | $63.36B | $112.32B | $63.15B | $114.53B | $63.49B | $115.82B | $59.11B | $112.74B |
| Total Investments | $3.75B | $3.23B | $17.42B | $3.26B | $15.99B | $3.00B | $25.47B | $3.22B | $13.80B | $3.29B | $20.22B | $2.91B | $19.44B | $2.66B | $27.83B | $2.67B | $31.94B | $2.97B | $18.86B | $5.99B |
| Total Debt | $17.91B | $23.75B | $- | $18.42B | $- | $21.03B | $- | $21.21B | $- | $21.24B | $- | $22.41B | $- | $21.65B | $- | $23.68B | $- | $24.93B | $- | $25.93B |
| Net Debt | $10.46B | $16.96B | $8.71B | $9.71B | $7.99B | $13.03B | $12.74B | $8.48B | $6.90B | $14.34B | $10.11B | $12.32B | $9.72B | $11.93B | $13.91B | $9.76B | $15.97B | $8.96B | $9.43B | $16.19B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $5.50B | $5.40B | $8.37B | $6.22B | $12.31B |
| Depreciation and Amortization | $3.59B | $3.78B | $3.42B | $3.35B | $3.68B |
| Deferred Income Tax | $-802.00M | $-1.23B | $-578.00M | $-356.00M | $-214.00M |
| Stock Based Compensation | $- | $- | $245.00M | $244.00M | $274.00M |
| Change in Working Capital | $-615.00M | $764.00M | $-707.00M | $1.41B | $-325.00M |
| Accounts Receivables | $-28.00M | $-397.00M | $-777.00M | $185.00M | $-134.00M |
| Inventory | $-477.00M | $-840.00M | $-927.00M | $-357.00M | $-593.00M |
| Accounts Payables | $789.00M | $402.00M | $452.00M | $451.00M | $86.00M |
| Other Working Capital | $-899.00M | $1.60B | $545.00M | $1.13B | $316.00M |
| Other Non Cash Items | $1.42B | $1.55B | $-225.00M | $3.00M | $-622.00M |
| Net Cash Provided by Operating Activities | $9.08B | $10.26B | $10.53B | $10.52B | $7.45B |
| Investments in Property Plant and Equipment | $-3.19B | $-3.25B | $-2.20B | $-2.04B | $-2.11B |
| Acquisitions Net | $-2.52B | $1.01B | $-858.00M | $-5.59B | $5.03B |
| Purchases of Investments | $- | $-134.00M | $-488.00M | $-311.00M | $-137.00M |
| Sales Maturities of Investments | $- | $42.00M | $- | $718.00M | $918.00M |
| Other Investing Activities | $1.31B | $-3.87B | $1.47B | $-68.00M | $-113.00M |
| Net Cash Used for Investing Activities | $-4.41B | $-6.20B | $-2.08B | $-7.30B | $3.59B |
| Debt Repayment | $-894.00M | $-3.14B | $-1.46B | $-2.65B | $-2.17B |
| Common Stock Issued | $187.00M | $195.00M | $188.00M | $186.00M | $203.00M |
| Common Stock Repurchased | $-302.00M | $-593.00M | $-497.00M | $-382.00M | $-822.00M |
| Dividends Paid | $-4.70B | $-4.45B | $-4.17B | $-4.01B | $-3.94B |
| Other Financing Activities | $-50.00M | $-63.00M | $116.00M | $-197.00M | $238.00M |
| Net Cash Used Provided by Financing Activities | $-5.76B | $-8.05B | $-5.82B | $-7.06B | $-6.49B |
| Effect of Forex Changes on Cash | $-13.00M | $-32.00M | $8.00M | $15.00M | $-64.00M |
| Net Change in Cash | $-1.27B | $-4.03B | $2.64B | $-3.82B | $4.49B |
| Cash at End of Period | $7.44B | $8.71B | $12.74B | $10.10B | $13.91B |
| Cash at Beginning of Period | $8.71B | $12.74B | $10.10B | $13.91B | $9.43B |
| Operating Cash Flow | $9.08B | $10.26B | $10.53B | $10.52B | $7.45B |
| Capital Expenditure | $-3.19B | $-3.02B | $-2.20B | $-2.04B | $-2.11B |
| Free Cash Flow | $5.89B | $7.35B | $8.32B | $8.48B | $5.33B |
Cash Flow Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.11B | $1.13B | $1.97B | $2.52B | $3.43B | $2.00B | $5.19B | $2.08B | $3.18B | $2.01B | $3.45B | $2.32B | $2.78B | $1.57B | $3.03B | $1.95B | $9.28B | $1.68B | $1.86B | $1.77B |
| Depreciation and Amortization | $1.46B | $- | $2.99B | $- | $1.86B | $- | $1.61B | $- | $1.83B | $- | $1.63B | $- | $1.73B | $- | $1.68B | $- | $2.02B | $- | $3.69B | $- |
| Deferred Income Tax | $-780.00M | $- | $-524.00M | $- | $-446.00M | $- | $-174.00M | $- | $-404.00M | $- | $-222.00M | $- | $-134.00M | $- | $82.00M | $- | $-296.00M | $- | $-935.00M | $- |
| Stock Based Compensation | $173.00M | $- | $283.00M | $- | $160.00M | $- | $245.00M | $- | $144.00M | $- | $244.00M | $- | $134.00M | $- | $274.00M | $- | $168.00M | $- | $252.00M | $- |
| Change in Working Capital | $-2.64B | $- | $1.58B | $- | $-819.00M | $- | $335.00M | $- | $-1.04B | $- | $874.00M | $- | $535.00M | $- | $69.00M | $- | $-394.00M | $- | $378.00M | $- |
| Accounts Receivables | $- | $- | $-182.00M | $- | $-215.00M | $- | $-795.00M | $- | $18.00M | $- | $-566.00M | $- | $751.00M | $- | $-650.00M | $- | $516.00M | $- | $-552.00M | $- |
| Inventory | $- | $- | $334.00M | $- | $-1.17B | $- | $195.00M | $- | $-1.12B | $- | $464.00M | $- | $-821.00M | $- | $430.00M | $- | $-1.02B | $- | $387.00M | $- |
| Accounts Payables | $82.00M | $- | $-95.00M | $- | $497.00M | $- | $341.00M | $- | $111.00M | $- | $540.00M | $- | $-89.00M | $- | $411.00M | $- | $-325.00M | $- | $218.00M | $- |
| Other Working Capital | $-2.72B | $- | $1.53B | $- | $73.00M | $- | $594.00M | $- | $-49.00M | $- | $436.00M | $- | $694.00M | $- | $-122.00M | $- | $438.00M | $- | $325.00M | $- |
| Other Non Cash Items | $2.10B | $-1.13B | $6.60B | $-2.52B | $4.15B | $-2.00B | $3.22B | $-2.08B | $4.91B | $-2.01B | $2.86B | $-2.32B | $3.47B | $-1.57B | $1.82B | $-1.95B | $-1.81B | $-1.68B | $6.90B | $-1.77B |
| Net Cash Provided by Operating Activities | $1.42B | $- | $6.70B | $- | $3.56B | $- | $6.70B | $- | $3.83B | $- | $5.77B | $- | $4.75B | $- | $3.52B | $- | $3.93B | $- | $4.57B | $- |
| Investments in Property Plant and Equipment | $-1.93B | $- | $-2.11B | $- | $-1.15B | $- | $-1.20B | $- | $-1.02B | $- | $-1.09B | $- | $-1.02B | $- | $-1.54B | $- | $-682.00M | $- | $-975.00M | $- |
| Acquisitions Net | $- | $- | $437.00M | $- | $575.00M | $- | $1.06B | $- | $-433.00M | $- | $-3.65B | $- | $-1.22B | $- | $-2.77B | $- | $-1.65B | $- | $-4.00M | $- |
| Purchases of Investments | $-2.09B | $- | $-1.48B | $- | $-2.52B | $- | $-378.00M | $- | $-110.00M | $- | $-240.00M | $- | $-71.00M | $- | $-120.00M | $- | $-17.00M | $- | $-14.00M | $- |
| Sales Maturities of Investments | $- | $- | $27.00M | $- | $15.00M | $- | $-101.00M | $- | $101.00M | $- | $- | $- | $- | $- | $-142.00M | $- | $10.51B | $- | $- | $- |
| Other Investing Activities | $607.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29.00M | $- | $-29.00M | $- | $87.00M | $- | $-87.00M | $- | $93.00M | $- |
| Net Cash Used for Investing Activities | $-3.41B | $- | $-3.13B | $- | $-3.08B | $- | $-616.00M | $- | $-1.46B | $- | $-4.96B | $- | $-2.34B | $- | $-4.49B | $- | $8.07B | $- | $-900.00M | $- |
| Debt Repayment | $5.25B | $- | $-2.62B | $- | $-249.00M | $- | $-43.00M | $- | $-911.00M | $- | $-310.00M | $- | $-2.34B | $- | $-634.00M | $- | $-1.02B | $- | $-944.00M | $- |
| Common Stock Issued | $21.00M | $- | $164.00M | $- | $31.00M | $- | $148.00M | $- | $40.00M | $- | $163.00M | $- | $23.00M | $- | $165.00M | $- | $38.00M | $- | $101.00M | $- |
| Common Stock Repurchased | $-302.00M | $- | $-230.00M | $- | $-363.00M | $- | $-137.00M | $- | $-360.00M | $- | $-242.00M | $- | $-140.00M | $- | $-461.00M | $- | $-361.00M | $- | $3.00M | $- |
| Dividends Paid | $-4.70B | $- | $- | $- | $-4.45B | $- | $- | $- | $-4.17B | $- | $- | $- | $-4.01B | $- | $- | $- | $-3.94B | $- | $- | $- |
| Other Financing Activities | $-175.00M | $- | $-150.00M | $- | $-176.00M | $- | $-184.00M | $- | $-206.00M | $- | $-51.00M | $- | $-147.00M | $- | $-153.00M | $- | $-125.00M | $- | $-33.00M | $- |
| Net Cash Used Provided by Financing Activities | $89.00M | $- | $-2.84B | $- | $-5.21B | $- | $-216.00M | $- | $-5.61B | $- | $-440.00M | $- | $-6.62B | $- | $-1.08B | $- | $-5.40B | $- | $-977.00M | $- |
| Effect of Forex Changes on Cash | $- | $- | $-13.00M | $- | $-19.00M | $- | $-32.00M | $- | $40.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-1.92B | $- | $717.00M | $- | $-4.74B | $- | $5.84B | $- | $-3.20B | $- | $376.00M | $- | $-4.19B | $- | $-2.05B | $- | $6.60B | $- | $2.69B | $- |
| Cash at End of Period | $6.79B | $- | $8.71B | $- | $7.99B | $- | $12.74B | $- | $6.90B | $- | $10.10B | $- | $9.72B | $- | $13.91B | $- | $15.97B | $- | $9.74B | $- |
| Cash at Beginning of Period | $8.71B | $- | $7.99B | $- | $12.74B | $- | $6.90B | $- | $10.10B | $- | $9.72B | $- | $13.91B | $- | $15.97B | $- | $9.37B | $- | $7.05B | $- |
| Operating Cash Flow | $1.42B | $- | $6.70B | $- | $3.56B | $- | $6.70B | $- | $3.83B | $- | $5.77B | $- | $4.75B | $- | $3.52B | $- | $3.93B | $- | $4.57B | $- |
| Capital Expenditure | $-1.89B | $- | $-2.11B | $- | $-1.15B | $- | $-1.20B | $- | $-1.02B | $- | $-1.09B | $- | $-1.02B | $- | $-1.54B | $- | $-682.00M | $- | $-975.00M | $- |
| Free Cash Flow | $-504.00M | $- | $4.59B | $- | $2.42B | $- | $5.50B | $- | $2.81B | $- | $4.67B | $- | $3.74B | $- | $1.98B | $- | $3.24B | $- | $3.59B | $- |
Sanofi Dividends
Explore Sanofi's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
4.00%
Dividend Payout Ratio
84.60%
Dividend Paid & Capex Coverage Ratio
1.15x
Sanofi Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $3.92 | $3.92 | May 12, 2025 | May 13, 2025 | May 14, 2025 | |
| $3.76 | $3.76 | May 13, 2024 | May 14, 2024 | May 15, 2024 | |
| $3.56 | $3.56 | May 30, 2023 | May 31, 2023 | June 01, 2023 | |
| $3.33 | $3.33 | May 06, 2022 | May 09, 2022 | May 10, 2022 | |
| $3.2 | $3.2 | May 05, 2021 | May 06, 2021 | May 07, 2021 | |
| $3.15 | $3.15 | May 04, 2020 | May 05, 2020 | May 06, 2020 | February 06, 2020 |
| $3.07 | $3.07 | May 09, 2019 | May 10, 2019 | May 13, 2019 | February 07, 2019 |
| $3.03 | $3.03 | May 11, 2018 | May 14, 2018 | May 15, 2018 | February 07, 2018 |
| $2.96 | $2.96 | May 16, 2017 | May 17, 2017 | May 18, 2017 | February 08, 2017 |
| $2.93 | $2.93 | May 10, 2016 | May 11, 2016 | May 12, 2016 | February 09, 2016 |
| $2.85 | $2.85 | May 11, 2015 | May 12, 2015 | May 13, 2015 | February 05, 2015 |
| $2.8 | $2.8 | May 12, 2014 | May 14, 2014 | May 15, 2014 | February 06, 2014 |
| $2.77 | $2.77 | May 09, 2013 | May 13, 2013 | May 14, 2013 | February 07, 2013 |
| $2.65 | $2.65 | May 10, 2012 | May 14, 2012 | May 15, 2012 | February 08, 2012 |
| $2.5 | $2.5 | May 16, 2011 | May 13, 2011 | June 16, 2011 | February 09, 2011 |
| $2.4 | $2.4 | May 20, 2010 | May 24, 2010 | May 25, 2010 | February 10, 2010 |
| $2.2 | $2.2 | April 23, 2009 | April 27, 2009 | April 28, 2009 | February 11, 2009 |
| $2.07 | $2.07 | May 16, 2008 | May 20, 2008 | May 21, 2008 | February 12, 2008 |
| $1.75 | $1.75 | June 07, 2007 | June 07, 2007 | February 13, 2007 | |
| $0.31 | $0.31 | November 29, 2006 |
Sanofi News
Read the latest news about Sanofi, including recent articles, headlines, and updates.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SAN.PA.